This page shows the latest head and neck cancer news and features for those working in and with pharma, biotech and healthcare.
lung cancer (NSCLC), gastric cancer and other cancers. ... cancer, lymphoma, NSCLC and mesothelioma, head and neck tumours.
The INTERLINK-1 study assessed the combination drug candidate to treat patients with head and neck cancer. ... signals observed in a non-randomised phase 1b/2 study of head and neck cancer.
Dr Ken Kato, chief of Head and Neck Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, said: “This data, which shows tislelizumab plus chemotherapy extended patients’ lives by a median of ... These results add to the growing body of
5T4 is a protein identified in cancer and stromal cells that aid tumour growth, and is often found in non-small cell lung cancer, pancreatic cancer, breast cancer and head and ... DF7001 could destroy 5T4+ expressing cells, including tumour cells,
metastatic head and neck squamous cell carcinoma (HNSCC). ... An interim analysis of the EMERGE study found that vopratelimab in combination with Bristol Myers Squibb’s Yervoy (ipilimumab) in non-small cell lung cancer (NSCLC) patients who had
advanced head and neck cancer patients who are unable to tolerate high-dose cisplatin in combination with radiotherapy. ... The drug is currently being evaluated in the phase 3 TrilynX study for the treatment of previously untreated high-risk locally
More from news
Approximately 9 fully matching, plus 113 partially matching documents found.
This could be a side effect of a condition such as stroke, motor neurone disease, multiple sclerosis, learning disability, dementia, Parkinson’s disease, head and neck injury or cancer. ... We are effectively made of water and the consequences of
hope was that - without the brake of PD-1 – the edited cells would attack and defeat the cancer. ... The work was reported in the journal Nature and, since then, another Chinese group has tested a similar approach in head and neck cancer.
Practitioners were concerned that a hasty introduction of the vaccine would lead to lower participation rates in cervical cancer screening programmes using the pap smear test. ... For example, the remarkable silence around the fact that some strains of
virus. INO-3112 generates killer T-cell responses to HPV 16 and 18 driven tumours and is in phase I / II clinical studies for cervical and head and neck cancers. ... Acquisition ‐ company. 847. Inovio. AZ/Medimmune. INO‐3112 vaccine in P1/2 for
Lonafarnib and tipifarnib are the most successful of the FTIs, currently in Phase II development for breast cancer, and acute myeloid leukaemia and glioma, respectively. ... Development in other oncological indications (chronic myeloid leukaemia,
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Prior to this, he was director of clinical oncology at Bristol-Myers Squibb where he worked on the clinical development of Erbitux (cetuximab), which is approved for colorectal cancer and head ... and neck cancer.
During his career, Dr Bryan has focused on drug discovery in oncology, and has a medical background in haematology and oncology. ... This experience will benefit VentiRx as it prepares to advance the development of VTX-2337 for patients with ovarian
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
the challenges of head and neck cancer. ... This cancer and its treatment can have life-changing consequences for patients’ appearance and ability to communicate, as well as mental health.
challenges of head and neck cancer. ... This cancer and its treatment can have life-changing consequences for patients’ appearance and ability to communicate, as well as mental health.
In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... Rubbing salt into BMS’s wounds, Merck's Keytruda snagged
Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...